Technology ID
TAB-2437
Antagonist of A3 Adenosine Receptor Fluorescent Probes for the Study of Diseases that Involve A3 Signaling
E-Numbers
E-073-2012-0
Lead Inventor
Jacobson, Kenneth (NIDDK)
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Oncology
Immunology
Dermatology
Development Status
- Early-stage
- In vitro data available
Lead IC
NIDDK
ICs
NIDDK
This molecular probe may serve as a companion tool to identify and stratify patient populations based on the prevalence of the target A3 adenosine receptors.
Small molecule drugs, A3AR-selective agonists, are currently in advanced clinical trials for the treatment of hepatocellular carcinoma, autoimmune inflammatory diseases, such as rheumatoid arthritis, psoriasis, and dry eye disease, and other conditions.
Small molecule drugs, A3AR-selective agonists, are currently in advanced clinical trials for the treatment of hepatocellular carcinoma, autoimmune inflammatory diseases, such as rheumatoid arthritis, psoriasis, and dry eye disease, and other conditions.
Commercial Applications
- Tools to study prevalence of this receptor on neutrophils, a predictor of response to agonist drugs.
Competitive Advantages
- Avoids the use of radioisotopes in this part of the R&D process.
Licensing Contact: